Hengrui Pharmaceuticals appoints Dr. Zhu Guoxin as senior vice president

Jiangsu Hengrui Medicine Co., Ltd. held the twentieth meeting of its ninth board of directors on December 3, 2025. All 11 directors attended the meeting, which complied with company regulations. The board unanimously approved the proposal to nominate and appoint Dr. Zhu Guoxin as the company's senior vice president.

Dr. Zhu Guoxin's term will begin from the date of approval and conclude at the expiry of the current board's term. He brings over 30 years of global cross-functional drug discovery leadership experience, spanning from target hypothesis to early clinical testing across multiple disease areas, including diabetes/obesity, immunology, neurological diseases, pain, and oncology.

Prior to joining Jiangsu Hengrui Medicine, Dr. Zhu served as vice president at Eli Lilly's New Drug R&D Center, where he led multiple discovery research and early development projects. He also chaired the small molecule strategy group and oversaw the research and delivery of over 100 small molecule clinical drug candidates. Additionally, he was a core member of the therapeutic area strategy group, contributing to investment portfolios and external collaborative research strategies across various modalities. Dr. Zhu holds bachelor's, master's, and doctoral degrees from Zhejiang University, Shanghai Institute of Organic Chemistry, and Pennsylvania State University, respectively. The proposal was approved with 11 votes in favor, 0 against, and 0 abstentions, having been reviewed by the company's board nomination committee.